Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Ernexa Therapeutics announced it remains on track to submit an IND application for its lead candidate ERNA-101 in the third quarter of 2026, with a first-in-human Phase 1 study planned for the fourth quarter. The company has completed manufacturing process development and initiated GMP production, milestones supported by a recently closed $10.5 million financing that funds operations for the next 12 to 18 months.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.